Stock Earnings

Question 1

HLS Therapeutics Inc'in temel mali tabloları nelerdir?

Accepted Answer

Son mali tabloya (Form-10K) göre, HLS Therapeutics Inc'in toplam varlıkları $159 olup, net loss $-19'dir.

Question 2

HLTRF'ün temel finansal oranları nelerdir?

Accepted Answer

HLS Therapeutics Inc'in cari oranı 1.8, net kâr marjı -33.92, hisse başına satış $1.75'dir.

Question 3

HLS Therapeutics Inc'in geliri segment veya coğrafya bazında nasıl dağılıyor?

Accepted Answer

HLS Therapeutics Inc largest revenue segment is Pharmaceutical, at a revenue of 77,565,856 in the most earnings release.For geography, Canada is the primary market for HLS Therapeutics Inc, at a revenue of 58,423,383.

Question 4

HLS Therapeutics Inc kârlı mı?

Accepted Answer

no, son mali tablolara göre HLS Therapeutics Inc'in net loss $-19'dir.

Question 5

HLS Therapeutics Inc'in herhangi bir yükümlülüğü var mı?

Accepted Answer

yes, HLS Therapeutics Inc'in yükümlülüğü 88'dir.

Question 6

HLS Therapeutics Inc'in tedavüldeki hisse sayısı kaçtır?

Accepted Answer

HLS Therapeutics Inc'in toplam tedavüldeki hisse sayısı 31.79'dir.

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenue	56	56	63	61	60	56
Revenue Growth (YoY)	-3%	-11%	3%	2%	7%	4%
Cost of Revenue	9	8	7	5	4	3
Gross Profit	46	47	55	56	56	52
Selling, General & Admin	29	32	33	35	32	31
Research & Development	--	--	--	--	--	--
Operating Expenses	53	56	67	70	62	64
Other Non Operating Income (Expenses)	--	--	--	--	0	0
Pretax Income	-14	-15	-27	-23	-11	-16
Income Tax Expense	0	4	0	0	1	-1
Net Income	-15	-19	-27	-23	-13	-15
Net Income Growth	-38%	-30%	17%	77%	-13%	-21%
Shares Outstanding (Diluted)	31.64	31.83	32.26	32.4	32.2	31.7
Shares Change (YoY)	-1%	-1%	0%	1%	2%	8%
EPS (Diluted)	-0.47	-0.61	-0.85	-0.73	-0.41	-0.48
EPS Growth	-37%	-28%	17%	78%	-15%	-28%
Free Cash Flow	11	7	15	16	15	-23
Free Cash Flow Per Share	0.34	0.21	0.46	0.49	0.46	-0.72
Gross Margin	82.14%	83.92%	87.3%	91.8%	93.33%	92.85%
Operating Margin	-10.71%	-16.07%	-17.46%	-21.31%	-10%	-21.42%
Profit Margin	-26.78%	-33.92%	-42.85%	-37.7%	-21.66%	-26.78%
Free Cash Flow Margin	19.64%	12.5%	23.8%	26.22%	25%	-41.07%
EBITDA	15	13	20	21	24	21
EBITDA Margin	26.78%	23.21%	31.74%	34.42%	40%	37.5%
D&A For EBITDA	21	22	31	34	30	33
EBIT	-6	-9	-11	-13	-6	-12
EBIT Margin	-10.71%	-16.07%	-17.46%	-21.31%	-10%	-21.42%
Effective Tax Rate	0%	-26.66%	0%	0%	-9.09%	6.25%

HLS Therapeutics Inc (HLTRF) Price

HLTRF Stock Price Chart

HLTRF Income

Follow-Up Questions